Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences doses first patient in Quad Phase III clinical program

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Study: sdNVP can lead to HIV treatment failure in women receiving drug to prevent infant infection

Study: sdNVP can lead to HIV treatment failure in women receiving drug to prevent infant infection

FDA grants approval for Abbott's antiretroviral medication Norvir

FDA grants approval for Abbott's antiretroviral medication Norvir

Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA

Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR

Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR

Pfizer’s Revatio Injection receives FDA approval

Pfizer’s Revatio Injection receives FDA approval

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences to present Viread Phase III clinical trial data

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Matrix Laboratories receives tentative FDA approval for its NDA

Matrix Laboratories receives tentative FDA approval for its NDA

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Antiretroviral therapy earlier yields better clinical outcomes

Antiretroviral therapy earlier yields better clinical outcomes

Gilead Sciences announces notification of ANDA filing for Atripla

Gilead Sciences announces notification of ANDA filing for Atripla

Tools for more accurate dosage of drugs against HIV/AIDS and malaria

Tools for more accurate dosage of drugs against HIV/AIDS and malaria

Antiretroviral drug efavirenz associated with better outcomes in HIV-infected adults

Antiretroviral drug efavirenz associated with better outcomes in HIV-infected adults